Latest On Adamas Pharmaceuticals, Inc (ADMS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-10-27 12:17 EST | News | Adamas Pharmaceuticals: An Acceptable Buyout At The Perfect Time | N/A |  |
| 2021-10-16 03:15 EST | News | Jasper more than doubles while M&A headlines weekly healthcare performers | N/A | |
| 2021-10-12 00:48 EST | News | Supernus to acquire Adamas in a deal worth up to $850 million | N/A | |
| 2021-10-12 00:46 EST | News | As Supernus acquires Adamas, other Parkinson's players mixed on the day | N/A | |
| 2021-08-09 22:16 EST | News | Adamas Pharma EPS beats by $0.02, beats on revenue | N/A | |
| 2021-08-09 22:15 EST | News | Adamas Pharmaceuticals, Inc. (ADMS) CEO Neil McFarlane on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 18:19 EST | News | Adamas secures new patents for Gocovri and ADS-4101 | N/A | |
| 2021-07-20 17:48 EST | News | Analysis finds Adamas Parkinson's drug provides motor activity improvements | N/A | |
| 2021-07-20 17:33 EST | News | Adamas Pharmaceuticals: Share Price Range-Bound Despite Steady Revenue Growth | N/A | |
| 2021-04-14 20:47 EST | News | Circling Back On Adamas Pharmaceuticals | N/A | |
| 2021-03-30 01:02 EST | News | Adamas announces new peer-reviewed data to support Gocovri benefit in Parkinson’s | N/A | |
| 2021-03-01 03:01 EST | Analyst Rating | The Analyst Target Price has decreased from $10.69 to $10.44. | Neutral | |
| 2021-02-25 18:35 EST | News | Adamas Pharmaceuticals stock under pressure on $55M equity raise | N/A | |
| 2021-02-25 18:33 EST | News | Adamas Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-25 03:02 EST | Analyst Rating | The Analyst Target Price has increased from $10.56 to $10.69. | Buy | |
| 2021-02-24 21:17 EST | News | Adamas Pharmaceuticals launches follow-on public offering | N/A | |
| 2021-02-24 11:02 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-24 03:16 EST | News | Adamas Pharma EPS misses by $0.14, beats on revenue | N/A | |
| 2021-02-24 03:15 EST | News | Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-24 03:01 EST | Earnings Estimate | An EPS average of -$0.82 is estimated for the 2022 year. | Sell | |
| 2021-02-24 03:01 EST | Earnings Estimate | An EPS average of -$0.34 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-10 15:02 EST | Analyst Rating | The Analyst Target Price has increased from $10.44 to $10.56. | Buy | |
| 2021-02-05 15:01 EST | Analyst Rating | The Analyst Target Price has increased from $10.06 to $10.44. | Buy | |
| 2021-02-03 03:01 EST | Analyst Rating | The Analyst Target Price has increased from $9.81 to $10.06. | Buy | |
| 2021-02-02 03:02 EST | News | Adamas Pharmaceuticals trading halted for news pending | N/A | |
| 2021-02-02 03:02 EST | News | Adamas' stock jumps on GOCOVRI's expanded FDA approval | N/A | |
| 2021-02-01 09:00 EST | News | Adamas gains 12% on settlement of patent litigation with Zydus | N/A | |
| 2021-01-30 23:00 EST | News | Adamas: How We Got Here And What The Future Brings | N/A | |
| 2021-01-29 07:02 EST | Analyst Rating | The Analyst Target Price has increased from $9.19 to $9.81. | Buy | |
| 2021-01-13 09:45 EST | News | Adamas Pharmaceuticals provides preliminary Q4 and FY figures | N/A | |
| 2020-12-13 03:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-02 14:48 EST | News | Adamas Pharma settles patent dispute with Osmotica for $7.5M | N/A | |
| 2020-12-02 14:48 EST | News | Adamas Pharma amends royalty-backed loan deal with Healthcare Royalty Partners | N/A | |
| 2020-11-25 11:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 20:05 EST | News | Adamas Pharmaceuticals: Unjustified Sell-Off Following Another Strong Quarter | N/A | |
| 2020-11-09 11:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 03:02 EST | Analyst Rating | The Analyst Target Price has decreased from $9.31 to $9.19. | Neutral | |
| 2020-11-08 17:01 EST | News | Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q3 2020 Results -Earnings Call Transcript | N/A | |
| 2020-11-06 15:02 EST | Earnings Estimate | An EPS average of -$0.41 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-06 01:17 EST | News | Adamas Pharma EPS beats by $0.05, misses on revenue | N/A | |
| 2020-11-02 17:00 EST | Insider Trade | Christopher B Prentiss has directly disposed of 2,050 shares and currently holds 78,890 shares. | Sell | |
| 2020-11-01 16:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-02 11:51 EST | News | Adamas Pharma names new CMO | N/A | |
| 2020-09-26 04:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 16:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-01 17:00 EST | Insider Trade | ANNA RICHO has directly acquired 10,000 shares and currently holds 20,000 shares. | Buy | |
| 2020-08-13 10:04 EST | News | Adamas Pharmaceuticals: Feeling Bullish After Impressive Growth In Q2 | N/A | |
| 2020-08-12 04:02 EST | Analyst Rating | The Analyst Target Price has decreased from $9.44 to $9.31. | Neutral | |
| 2020-08-11 08:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-09 08:02 EST | Financials | Company financials have been released. | Neutral | |
About Adamas Pharmaceuticals, Inc (ADMS):
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
General
- Name Adamas Pharmaceuticals, Inc
- Symbol ADMS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 138
- Fiscal Year EndDecember
- IPO Date2014-04-10
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.adamaspharma.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 2.09
- Enterprise Value Revenue 4.03
- Enterprise Value EBITDA 0.11
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.61
- Next Year EPS Estimate -$0.88
- Next Quarter EPS Estimate -$0.45
- Profit Margin -77%
- Operating Margin -53%
- Return on Assets -17%
- Revenue 74.46 million
- Earnings Per Share -$4.25
- Revenue Per Share $2.63
- Gross Profit 72.42 million
- Quarterly Earnings Growth 28.5%
View More
Highlights
- Market Capitalization 248.54 million
- EBITDA -101027000
- PEG Ratio -0.06
- Analyst Target Price $10.44
- Book Value Per Share $0.71
View More
Share Statistics
- Shares Outstanding 44.94 million
- Shares Float 22.54 million
- % Held by Insiders 274%
- % Held by Institutions 68.33%
- Shares Short 1.99 million
- Shares Short Prior Month 923484
- Short Ratio 1.41
- Short % of Float 8%
- Short % of Shares Outstanding 7%
View More
Technicals
- Beta 2.68
- 52 Week High $9.15
- 52 Week Low $2.31
- 50 Day Moving Average 5.49
- 200 Day Moving Average 4.7
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Adamas Pharmaceuticals, Inc (ADMS) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Adamas Pharmaceuticals, Inc (ADMS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-23 | $21.01 million | -$0.64 | -$0.52 | -23.67% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.42 | -$0.48 | 12.95% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.37 | -$0.61 | 39.34% |
| 2020-03-31 | 2020-05-07 | $14.48 million | -$0.59 | -$0.77 | 23.38% |
| 2019-12-31 | 2020-02-25 | $16.35 million | -$0.83 | -$0.83 | 0.3% |
| 2019-09-30 | 2019-11-07 | $13.93 million | -$0.99 | -$0.87 | -13.36% |
| 2019-06-30 | 2019-08-08 | $12.69 million | -$0.90 | -$0.99 | 8.63% |
| 2019-03-31 | 2019-05-09 | $11.67 million | -$1.08 | -$1.15 | 5.73% |
| 2018-12-31 | 2019-03-04 | $13.32 million | -$1.06 | -$1.32 | 19.7% |
| 2018-09-30 | 2018-11-01 | $10.61 million | -$1.22 | -$1.34 | 9.16% |
| 2018-06-30 | 2018-08-02 | $7.57 million | -$1.26 | -$1.41 | 10.78% |
| 2018-03-31 | 2018-05-03 | $2.55 million | -$1.35 | -$1.37 | 1.36% |
| 2017-12-31 | 2018-02-22 | $568000 | -$1.28 | -$1.18 | -8.6% |
| 2017-09-30 | 2017-11-02 | $1000 | -$1.04 | -$0.98 | -6.48% |
| 2017-06-30 | 2017-08-08 | $2000 | -$0.93 | -$0.81 | -15.28% |
| 2017-03-31 | 2017-05-09 | $N/A | -$0.72 | -$0.71 | -1.88% |
| 2016-12-31 | 2017-02-28 | $37000 | -$0.68 | -$0.80 | 15.42% |
| 2016-09-30 | 2016-11-03 | $138000 | -$0.66 | -$0.83 | 20.07% |
| 2016-06-30 | 2016-08-04 | $222000 | -$0.78 | -$0.71 | -10.23% |
| 2016-03-31 | 2016-05-10 | $175000 | -$0.65 | -$0.74 | 12.16% |
| 2015-12-31 | 2016-02-23 | $524000 | -$0.58 | -$0.86 | 32.87% |
| 2015-09-30 | 2015-11-12 | $768000 | -$0.81 | -$0.83 | 2.41% |
| 2015-06-30 | 2015-08-11 | $398000 | -$0.78 | -$0.72 | -8.33% |
| 2015-03-31 | 2015-05-13 | $226000 | -$0.69 | -$0.74 | 6.76% |
| 2014-12-31 | 2015-03-03 | $30.3 million | $0.50 | -$0.24 | 308.33% |
| 2014-09-30 | 2014-11-04 | $215000 | -$0.57 | -$0.44 | -29.55% |
| 2014-06-30 | 2014-08-07 | $25.15 million | $0.88 | $0.81 | 8.64% |
| 2014-03-31 | 2014-05-14 | $176000 | -$0.67 |
Adamas Pharmaceuticals, Inc (ADMS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 2.4 million | N/A | N/A | 2.47 million | 5.18 million |
| Income Before Tax | -18.27 million | N/A | N/A | -16.65 million | -23.08 million |
| Selling General Administrative | 32.99 million | N/A | N/A | 24.55 million | 30.29 million |
| Gross Profit | 20.41 million | N/A | N/A | 13.91 million | 15.91 million |
| Ebit | -14.88 million | N/A | N/A | -12.79 million | -19.56 million |
| Operating Income | -14.98 million | N/A | N/A | -13.11 million | -19.56 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 21.01 million | N/A | N/A | 14.48 million | 16.35 million |
| Cost of Revenue | 597000 | N/A | N/A | 572000 | 442000 |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -3.52 million |
| Net Income From Continuing Operations | -18.27 million | N/A | N/A | -16.65 million | -23.08 million |
| Net Income Applicable to Common Shares | -18.27 million | -11.92 million | -10.57 million | -16.65 million | -23.08 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -3.01 million | N/A | N/A | 27.76 million |
| Change to Liabilities | 2.05 million | N/A | -3.3 million | N/A | 431000 |
| Total Cash Flow from Investing Activities | 31 million | N/A | -2.96 million | N/A | 27.76 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | 223000 | N/A | N/A | 133000 |
| Change to Operating Activities | -4.38 million | N/A | -3.02 million | N/A | -1.38 million |
| Change in Cash | N/A | -15 million | N/A | N/A | 9.24 million |
| Total Cash from Operating Activities | -10.85 million | -12.22 million | -17.31 million | N/A | -18.66 million |
| Depreciation | N/A | 224000 | N/A | N/A | 266000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | -432000 | N/A | N/A | -46000 |
| Change to Account Receivables | N/A | -861000 | N/A | N/A | 875000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 4.96 million | N/A | 5.63 million | N/A | 8.77 million |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 170.01 million | N/A | 157.47 million | N/A | N/A |
| Total Stockholder Equity | -49.98 million | N/A | -24.41 million | N/A | N/A |
| Other Current Liabilities | 1.9 million | 9.4 million | 1.82 million | N/A | N/A |
| Total Assets | 120.03 million | N/A | 133.07 million | N/A | N/A |
| Common Stock | 34000 | 33000 | N/A | 33000 | N/A |
| Other Current Assets | 13.04 million | N/A | N/A | N/A | N/A |
| Retained Earnings | -505.29 million | -487.01 million | -475.1 million | -464.53 million | N/A |
| Other Liabilities | N/A | 2.43 million | N/A | 2.5 million | N/A |
| Other Assets | N/A | 38000 | N/A | 1.01 million | N/A |
| Cash | 71.66 million | N/A | 30.54 million | N/A | N/A |
| Total Current Liabilities | 34.87 million | 31.49 million | 21.22 million | N/A | N/A |
| Other Stockholder Equity | N/A | 32000 | N/A | 73000 | N/A |
| Property, Plant & Equipment | 1.6 million | 8.82 million | N/A | 9.92 million | N/A |
| Total Current Assets | 111.74 million | 123.94 million | 123.69 million | N/A | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -49.98 million | -34.62 million | N/A | -15.85 million | N/A |
| Short Term Investments | 11.71 million | N/A | 72.88 million | N/A | N/A |
| Long Term Debt | 126.31 million | N/A | 126.3 million | N/A | N/A |
| Inventory | 7.29 million | 6.85 million | 5.85 million | N/A | N/A |
| Accounts Payable | 29.31 million | 4.71 million | 2.47 million | N/A | N/A |
Adamas Pharmaceuticals, Inc (ADMS) Chart:
Adamas Pharmaceuticals, Inc (ADMS) News:
Below you will find a list of latest news for Adamas Pharmaceuticals, Inc (ADMS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Adamas Pharmaceuticals, Inc (ADMS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Adamas Pharmaceuticals, Inc (ADMS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000036/0001328143-20-000036-index.htm |
| 2019-09-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1328143/000000000019013748/0000000000-19-013748-index.htm |
| 2019-10-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1328143/000000000019014560/0000000000-19-014560-index.htm |
| 2019-11-20 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1328143/000000000019015664/0000000000-19-015664-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000009375119000043/0000093751-19-000043-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000021545719006712/0000215457-19-006712-index.htm |
| 2018-10-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000031506618002417/0000315066-18-002417-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000083423720004693/0000834237-20-004693-index.htm |
| 2020-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000083423720009908/0000834237-20-009908-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000089914019000204/0000899140-19-000204-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000089914020000165/0000899140-20-000165-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091420819000068/0000914208-19-000068-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091420820000025/0000914208-20-000025-index.htm |
| 2019-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091957419000649/0000919574-19-000649-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091957419001196/0000919574-19-001196-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091957420001124/0000919574-20-001124-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000091957420001498/0000919574-20-001498-index.htm |
| 2019-06-19 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000093583619000346/0000935836-19-000346-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000093583620000104/0000935836-20-000104-index.htm |
| 2019-01-02 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000117266119000002/0001172661-19-000002-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000119312519040928/0001193125-19-040928-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000119312520034818/0001193125-20-034818-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036396/0001209191-18-036396-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036405/0001209191-18-036405-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036414/0001209191-18-036414-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036418/0001209191-18-036418-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036426/0001209191-18-036426-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036428/0001209191-18-036428-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118036430/0001209191-18-036430-index.htm |
| 2018-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118039249/0001209191-18-039249-index.htm |
| 2018-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118039257/0001209191-18-039257-index.htm |
| 2018-09-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118051991/0001209191-18-051991-index.htm |
| 2018-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118057797/0001209191-18-057797-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118063937/0001209191-18-063937-index.htm |
| 2018-12-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118064120/0001209191-18-064120-index.htm |
| 2018-12-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919118064320/0001209191-18-064320-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020763/0001209191-19-020763-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020769/0001209191-19-020769-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020779/0001209191-19-020779-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020785/0001209191-19-020785-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020792/0001209191-19-020792-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024239/0001209191-19-024239-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024240/0001209191-19-024240-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024242/0001209191-19-024242-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024244/0001209191-19-024244-index.htm |
| 2019-04-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024248/0001209191-19-024248-index.htm |
| 2019-06-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119034483/0001209191-19-034483-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035047/0001209191-19-035047-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035051/0001209191-19-035051-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035054/0001209191-19-035054-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035058/0001209191-19-035058-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035061/0001209191-19-035061-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035064/0001209191-19-035064-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035069/0001209191-19-035069-index.htm |
| 2019-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035685/0001209191-19-035685-index.htm |
| 2019-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119038602/0001209191-19-038602-index.htm |
| 2019-07-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119042978/0001209191-19-042978-index.htm |
| 2019-09-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119049493/0001209191-19-049493-index.htm |
| 2019-09-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119049927/0001209191-19-049927-index.htm |
| 2019-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119049941/0001209191-19-049941-index.htm |
| 2019-09-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119050078/0001209191-19-050078-index.htm |
| 2019-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119050455/0001209191-19-050455-index.htm |
| 2019-11-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919119055838/0001209191-19-055838-index.htm |
| 2020-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120004717/0001209191-20-004717-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020266/0001209191-20-020266-index.htm |
| 2020-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020269/0001209191-20-020269-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020527/0001209191-20-020527-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034775/0001209191-20-034775-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034776/0001209191-20-034776-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034777/0001209191-20-034777-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034779/0001209191-20-034779-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034782/0001209191-20-034782-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034809/0001209191-20-034809-index.htm |
| 2020-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034864/0001209191-20-034864-index.htm |
| 2020-09-01 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120048933/0001209191-20-048933-index.htm |
| 2020-09-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120048935/0001209191-20-048935-index.htm |
| 2020-11-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1328143/000120919120056424/0001209191-20-056424-index.htm |
| 2019-03-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000131924419000031/0001319244-19-000031-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000131924420000040/0001319244-20-000040-index.htm |
| 2018-10-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814318000004/0001328143-18-000004-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814318000005/0001328143-18-000005-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814318000006/0001328143-18-000006-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000002/0001328143-19-000002-index.htm |
| 2019-03-04 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/0001328143-19-000011-index.htm |
| 2019-03-04 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000013/0001328143-19-000013-index.htm |
| 2019-03-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000014/0001328143-19-000014-index.htm |
| 2019-04-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000016/0001328143-19-000016-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000019/0001328143-19-000019-index.htm |
| 2019-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000020/0001328143-19-000020-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000026/0001328143-19-000026-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000027/0001328143-19-000027-index.htm |
| 2019-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000029/0001328143-19-000029-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000035/0001328143-19-000035-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000036/0001328143-19-000036-index.htm |
| 2019-09-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000038/0001328143-19-000038-index.htm |
| 2019-10-07 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000040/0001328143-19-000040-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000049/0001328143-19-000049-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000050/0001328143-19-000050-index.htm |
| 2019-11-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000051/0001328143-19-000051-index.htm |
| 2019-11-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000053/0001328143-19-000053-index.htm |
| 2019-11-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000055/0001328143-19-000055-index.htm |
| 2019-12-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000058/0001328143-19-000058-index.htm |
| 2019-12-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814319000059/0001328143-19-000059-index.htm |
| 2020-01-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000002/0001328143-20-000002-index.htm |
| 2020-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000004/0001328143-20-000004-index.htm |
| 2020-02-25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/0001328143-20-000012-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000013/0001328143-20-000013-index.htm |
| 2020-02-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000015/0001328143-20-000015-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000018/0001328143-20-000018-index.htm |
| 2020-04-23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000020/0001328143-20-000020-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000028/0001328143-20-000028-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000029/0001328143-20-000029-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000032/0001328143-20-000032-index.htm |
| 2020-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000034/0001328143-20-000034-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000036/0001328143-20-000036-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000042/0001328143-20-000042-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000043/0001328143-20-000043-index.htm |
| 2020-09-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000045/0001328143-20-000045-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000050/0001328143-20-000050-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000052/0001328143-20-000052-index.htm |
| 2020-11-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1328143/000132814320000054/0001328143-20-000054-index.htm |
| 2020-08-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000149315220016532/0001493152-20-016532-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000160454119000002/0001604541-19-000002-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1328143/000160454120000003/0001604541-20-000003-index.htm |
| 2018-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1328143/000162828018005106/0001628280-18-005106-index.htm |
| 2018-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1328143/000162828018005107/0001628280-18-005107-index.htm |
| 2018-05-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000162828018005826/0001628280-18-005826-index.htm |
| 2018-05-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000162828018005830/0001628280-18-005830-index.htm |
| 2018-06-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000162828018007648/0001628280-18-007648-index.htm |
| 2018-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1328143/000162828018010334/0001628280-18-010334-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000162828018010338/0001628280-18-010338-index.htm |
| 2018-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000162828018011880/0001628280-18-011880-index.htm |
| 2018-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1328143/000162828018012035/0001628280-18-012035-index.htm |
| 2019-12-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1328143/999999999519002725/9999999995-19-002725-index.htm |
| 2019-09-11 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1328143/999999999719006771/9999999997-19-006771-index.htm |
| 2019-09-26 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1328143/999999999719007128/9999999997-19-007128-index.htm |
Adamas Pharmaceuticals, Inc (ADMS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adamas Pharmaceuticals, Inc (ADMS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 274%Institutional Ownership: 6833%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-09-16 | Neil F. McFarlane | Chief Executive Officer | Buy | 125,000.00 | 125,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119049941/0001209191-19-049941-index.htm | ||
| 2019-03-20 | Gregory T Went | Chief Executive Officer | Sell | 6,319.00 | 7.99 | 50,488.81 | 176,291.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020763/0001209191-19-020763-index.htm |
| 2018-12-20 | Christopher B Prentiss | Chief Accounting Officer | Sell | 228.00 | 7.51 | 1,712.28 | 18,226.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118064120/0001209191-18-064120-index.htm |
| 2019-03-20 | Rajiv Patni | Chief Medical Officer | Sell | 2,374.00 | 8.00 | 18,992.00 | 19,141.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020785/0001209191-19-020785-index.htm |
| 2018-11-07 | Gregory T Went | Chief Executive Officer | Buy | 3,850.00 | 12.98 | 49,956.45 | 199,242.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118057797/0001209191-18-057797-index.htm |
| 2020-08-29 | ANNA RICHO | Director | Buy | 10,000.00 | 20,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120048935/0001209191-20-048935-index.htm | ||
| 2020-03-18 | Neil F. McFarlane | Chief Executive Officer | Buy | 100,000.00 | 225,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020527/0001209191-20-020527-index.htm | ||
| 2019-04-08 | Gregory T Went | Chief Executive Officer | Buy | 56,250.00 | 232,541.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024248/0001209191-19-024248-index.htm | ||
| 2019-03-20 | ALFRED G MERRIWEATHER | Chief Financial Officer | Sell | 857.00 | 7.99 | 6,847.43 | 24,603.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020792/0001209191-19-020792-index.htm |
| 2018-09-21 | ALFRED G MERRIWEATHER | Chief Financial Officer | Sell | 1,665.00 | 19.18 | 31,934.70 | 25,460.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118051991/0001209191-18-051991-index.htm |
| 2019-03-20 | Christopher B Prentiss | Chief Accounting Officer | Sell | 1,185.00 | 8.00 | 9,480.00 | 29,541.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020779/0001209191-19-020779-index.htm |
| 2018-12-27 | Christopher B Prentiss | Chief Accounting Officer | Buy | 12,500.00 | 30,726.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118064320/0001209191-18-064320-index.htm | ||
| 2019-03-20 | Jennifer J Rhodes | CBO, GC & Compliance Officer | Sell | 1,792.00 | 7.99 | 14,318.08 | 31,612.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119020769/0001209191-19-020769-index.htm |
| 2018-12-20 | Jennifer J Rhodes | CBO, GC & Compliance Officer | Sell | 425.00 | 7.52 | 3,196.00 | 33,404.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118063937/0001209191-18-063937-index.htm |
| 2018-06-21 | Jennifer J Rhodes | CBO, GC & Compliance Officer | Sell | 1,002.00 | 25.48 | 25,530.96 | 33,794.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118039257/0001209191-18-039257-index.htm |
| 2019-07-22 | Christopher B Prentiss | Chief Accounting Officer | Sell | 1,082.00 | 6.00 | 6,492.00 | 47,209.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119042978/0001209191-19-042978-index.htm |
| 2019-09-20 | ALFRED G MERRIWEATHER | Chief Financial Officer | Sell | 1,584.00 | 6.91 | 10,945.44 | 48,019.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119050455/0001209191-19-050455-index.htm |
| 2019-04-08 | Christopher B Prentiss | Chief Accounting Officer | Buy | 18,750.00 | 48,291.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024242/0001209191-19-024242-index.htm | ||
| 2018-06-21 | RICHARD KING | Chief Operating Officer | Sell | 2,501.00 | 25.48 | 63,725.48 | 48,856.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919118039249/0001209191-18-039249-index.htm |
| 2019-04-08 | Rajiv Patni | Chief Medical Officer | Buy | 30,000.00 | 49,141.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024240/0001209191-19-024240-index.htm | ||
| 2019-04-08 | ALFRED G MERRIWEATHER | Chief Financial Officer | Buy | 25,000.00 | 49,603.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024239/0001209191-19-024239-index.htm | ||
| 2020-06-03 | John A MacPhee | Director | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034779/0001209191-20-034779-index.htm | ||
| 2020-06-03 | Mardi Dier | Director | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034777/0001209191-20-034777-index.htm | ||
| 2020-06-03 | MARTHA J DEMSKI | Director | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034776/0001209191-20-034776-index.htm | ||
| 2020-06-03 | MICHAEL BIGHAM | Director | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034775/0001209191-20-034775-index.htm | ||
| 2020-06-03 | William W. Ericson | Director | Buy | 5,000.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034864/0001209191-20-034864-index.htm | ||
| 2020-06-03 | IVAN M LIEBERBURG | Director | Buy | 5,000.00 | 53,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034809/0001209191-20-034809-index.htm | ||
| 2019-09-17 | DAVID L MAHONEY | Director | Buy | 33,332.00 | 1.76 | 58,497.66 | 57,153.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119050078/0001209191-19-050078-index.htm |
| 2019-04-08 | Jennifer J Rhodes | CBO, GC & Compliance Officer | Buy | 30,000.00 | 61,612.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119024244/0001209191-19-024244-index.htm | ||
| 2020-06-03 | DAVID L MAHONEY | Director | Buy | 5,000.00 | 62,153.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120034782/0001209191-20-034782-index.htm | ||
| 2019-06-20 | Jennifer J Rhodes | CBO, GC & Compliance Officer | Sell | 940.00 | 5.35 | 5,029.00 | 63,114.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119038602/0001209191-19-038602-index.htm |
| 2019-06-07 | Vijay Shreedhar | Chief Commercial Officer | Buy | 68,750.00 | 68,750.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119035685/0001209191-19-035685-index.htm | ||
| 2020-01-21 | Christopher B Prentiss | Chief Financial Officer | Sell | 1,269.00 | 5.92 | 7,512.48 | 70,940.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120004717/0001209191-20-004717-index.htm |
| 2019-11-07 | Christopher B Prentiss | Chief Financial Officer | Buy | 25,000.00 | 72,209.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919119055838/0001209191-19-055838-index.htm | ||
| 2020-11-02 | Christopher B Prentiss | Chief Financial Officer | Sell | 2,050.00 | 3.21 | 6,580.50 | 78,890.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120056424/0001209191-20-056424-index.htm |
| 2020-03-17 | Christopher B Prentiss | Chief Financial Officer | Buy | 10,000.00 | 80,940.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020266/0001209191-20-020266-index.htm | ||
| 2020-03-17 | Vijay Shreedhar | Chief Commercial Officer | Buy | 23,750.00 | 95,000.00 | https://www.sec.gov/Archives/edgar/data/1328143/000120919120020269/0001209191-20-020269-index.htm |